SCHEMBL2434508

SCHEMBL2434508

Cc1cc(C(N)=O)c(NCCC(F)(F)F)cc1C(=O)O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CISD1 Q9NZ45 3/20 0.34
TTK P33981 7/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
ALDH1A1 P00352 2/20 0.33
CD38 P28907 2/20 0.33
MAPK14 Q16539 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
GUCY1A1 Q02108 1/20 0.33
GUCY1B1 Q02153 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33
AKR1C1 Q04828 1/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CYP3A4 P08684 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4010874 0.92 GUCY1A1 (0.40) CISD1HSP90AA1HSP90AB1GUCY1A1GUCY1B1
SCHEMBL2422093 0.84 APEX1 (0.36) CISD1ALDH1A1KDM4EMAPTHPGD
SCHEMBL2431005 0.83 CISD1 (0.49) CISD1HSP90AA1HSP90AB1ALDH1A1MAPK14
SCHEMBL3975516 0.82 RXRB (0.34) CISD1HSP90AA1HSP90AB1MAPK14RXRA
SCHEMBL3980322 0.80 HSP90AA1 (0.40) CISD1HSP90AA1HSP90AB1CD38
SCHEMBL4258452 0.80 MEN1 (0.34) CISD1HSP90AA1HSP90AB1MAPK14RXRA
SCHEMBL2426202 0.80 CISD1 (0.52) CISD1
SCHEMBL2424146 0.80 ALDH1A1 (0.40) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL28813041 0.80 MAPK14 (0.39) ALDH1A1MAPK14KDM4EMAPTHPGD
SCHEMBL2422460 0.79 JAK2 (0.40) CISD1HSP90AA1HSP90AB1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101910168-B Tropane compounds EXELIXIS INC 2014-07-30 CN disclosed
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8012956-B2 Tropane compounds EXELIXIS, INC. (US) 2011-09-06 US disclosed
CN-101910168-A Tropane compounds EXELIXIS INC 2010-12-08 CN disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP disclosed
EP-2074120-B1 TROPANE COMPOUNDS EXELIXIS INC (US) 2010-03-03 EP disclosed
EP-2074120-A1 TROPANE COMPOUNDS Exelixis, Inc. (US) 2009-07-01 EP disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
US-20090163471-A1 Tropane compounds EXELIXIS, INC. 2009-06-25 US disclosed
WO-2009055077-A1 TROPANE COMPOUNDS EXELIXIS, INC. (US) 2009-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163471-A1 Tropane compounds ADRA1B, ADRA2B, ADRB2 CISD1 4213/4885TTK 3715/4885HSP90AA1 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.